Guardant Health, Northwestern University Collaborate
News Nov 25, 2016
Guardant Health has announced that it has signed a deal with Northwestern University making Guardant360 the preferred liquid biopsy test for patients with advanced cancer treated at Northwestern's Robert H. Lurie Comprehensive Cancer Center.
Guardant said that the agreement also covers multiple large-scale prospective clinical trials in which researchers at the Lurie center will use its technology. Lurie Center Director Leonidas Platanias said in a statement that Lurie's growing OncoSET (Sequence, Evaluate, Treat) program will benefit from Guardant Health's non-invasive technology.
On the research side, every patient evaluated within the Lurie Cancer Center OncoSET Program will be enrolled in one of several prospective clinical trials exploring additional clinical uses of liquid biopsy, Guardant said. The partners also plan to track the outcomes of patients whose treatment selection was guided by Guardant360.
"This collaboration will help us determine the value of prospective molecular monitoring in patients with advanced disease by exploring the potential of liquid biopsy specifically, and precision oncology in general, to impact lives," added Northwestern's Massimo Cristofanilli, director of the OncoSET program.
Source: Story from Guardant Health. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
12th Edition of International Conference on Infectious Diseases
Apr 22 - Apr 23, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
33rd Global Experts Meeting on Cancer Science and Therapy
Apr 29 - Apr 30, 2019